Key clinical point: Researchers have identified genetic and chromosomal markers that may predict worse prognosis in patients with chronic lymphocytic leukemia.
Major finding: A single 11q22 deletion, lacking an ATM mutation on the other allele, resulted in the shortest progression-free survival.
Study details: A genetic analysis of 177 patients with chronic lymphocytic leukemia treated with rituximab-based regimens.
Disclosures: The study was funded by the Ministry of Health of the Czech Republic. The authors reported having no conflicts of interest.
Spunarova M et al. Leuk Res. 2019 Jun;81:75-81.